Novavax achieves 80% efficacy in clinical trials

(ČIA) The Novavax vaccine, part of which is manufactured in a plant in the Czech Republic, performs Phase 3 trials in the United Kingdom and 2B in South Africa with 90% efficiency. The company has stated that the substance is also effective against the African mutation of the virus. As ČIANEWS reported earlier, the part of the antigen vaccine produced in the Czech Republic is to be directed for final assembly to another location, probably to Germany. Prime Minister Andrej Babiš told CNN Prima NEWS that supplies of the vaccine could begin in April 2021.



Register newsletter

Get to know about Nordic Chamber, our press releases and all news, straight to your inbox.